Targeted ablation at stable atrial fibrillation sources improves success over conventional ablation in high-risk patients: a substudy of the CONFIRM Trial.
Targeted ablation at stable atrial fibrillation sources improves success over conventional ablation in high-risk patients: a substudy of the CONFIRM Trial.
复制标题
DOI:
10.1016/j.cjca.2013.07.672
复制
发表时间:
2013-10
期刊:
影响因子:
--
通讯作者:
CONFIRM Investigators
中科院分区:
文献类型:
--
作者:
Baykaner T;Clopton P;Lalani GG;Schricker AA;Krummen DE;Narayan SM;CONFIRM Investigators
Pulmonary vein (PV) isolation has disappointing results in patients with obesity, heart failure, obstructive sleep apnea (OSA) and enlarged left atria (LA), for unclear reasons. We hypothesized that these comorbidities cause higher numbers or non-PV locations of AF sources, where targeted source ablation (Focal Impulse and Rotor Modulation, FIRM) should improve the single-procedure success of ablation. The CONFIRM trial prospectively enrolled 92 patients at 107 AF ablation procedures, in whom computational mapping identified AF rotors or focal sources. Patients underwent FIRM plus conventional ablation (FIRM-guided), or conventional ablation only, and were evaluated for recurrent AF quarterly with rigorous, often implanted, monitoring. We report the n=73 patients undergoing first ablation in whom demographic information was available (n= 52 conventional, n=21 FIRM-guided). Stable sources for AF were found in 97.1% of patients. The numbers of concurrent sources per patient (2.1±1.1) rose with LA diameter (p=0.021), lower LV ejection fraction (p=0.039), and the presence of obstructive sleep apnea (OSA, p=0.002) or hypomagnesemia (p=0.017). Right atrial sources were associated with obesity (BMI≥30 kg/m2, p=0.015). In patients with obesity, hypertension, OSA and LA diameter > 40 mm, single-procedure freedom from AF was >80% by FIRM-guided versus <50% by conventional ablation (all; p<0.05). Patients with ‘difficult to treat’ AF exhibit more concurrent AF sources in more widespread biatrial distributions than other patients. These mechanisms explain the disappointing results of PV isolation, and how FIRM can identify patient-specific AF sources to enable successful ablation in this population.
登录
查看更多内容
影响因子:
24
作者:
Narayan, Sanjiv M.;Krummen, David E.;Clopton, Paul;Shivkumar, Kalyanam;Miller, John M.
通讯作者:
Miller, John M.
影响因子:
37.8
作者:
Charitos, Efstratios I.;Stierle, Ulrich;Hanke, Thorsten
通讯作者:
Hanke, Thorsten
影响因子:
24
作者:
Chen, MS;Marrouche, NF;Natale, A
通讯作者:
Natale, A
影响因子:
39.3
作者:
Berruezo, Antonio;Tamborero, David;Brugada, Josep
通讯作者:
Brugada, Josep
影响因子:
24
作者:
Narayan, Sanjiv M.;Krummen, David E.;Miller, John M.
通讯作者:
Miller, John M.